Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

GSK announced in January that its novel chronic hepatitis B (CHB) successfully met primary goals in two pivotal phase 3 ...

Scientists have uncovered a surprising viral shortcut that turns moving cells into delivery vehicles for infection. Instead ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current antiviral therapies, such as neuraminidase inhibitors and ...